Pfiz­er's Al­bert Bourla turns to an ac­com­plished deal­mak­er, strat­e­gy ex­pert for its next CFO

4 years ago
Pharma

Van­da takes FDA to court again, this time seek­ing more in­fo on a re­jec­tion let­ter

4 years ago
FDA+

AACR22: Bris­tol My­er­s' Op­di­vo is yet to reach sur­vival end­point in ear­ly-stage lung can­cer. But will it mat­ter?

4 years ago
R&D

Mer­ck ex­tends pact with NK cell spe­cial­ists at Arti­va; Re­gen­eron-al­lied biotech pen­cils in $15M IPO

4 years ago
News Briefing

Covid-19 roundup: Gavi rais­es $4.8B in pledged funds; Japan can­cels or­der of 40M re­main­ing As­traZeneca shots

4 years ago
Coronavirus

Pa­tient death trig­gers a sec­ond clin­i­cal hold for Curis as FDA seeks more da­ta

4 years ago
R&D
FDA+

Ger­many deal with Cure­Vac and GSK primed for 80M mR­NA vac­cines a year

4 years ago
Manufacturing

J&J takes Crohn's med Ste­lara in new di­rec­tion, with bold­er and brighter out­look

4 years ago
Pharma
Marketing

Eli Lil­ly flesh­es out more PhI­II da­ta for Dupix­ent chal­lenger as AD ri­val­ry heats up

4 years ago
R&D

The one ear­ly biotech bright spot at #AACR22 just turned red

4 years ago
R&D

BioN­Tech to ex­plore po­ten­tial of de­liv­er­ing mR­NA vac­cines oral­ly with new part­ner

4 years ago
Deals
R&D

Stealth UK biotech in-li­cens­es Lil­ly can­di­dates in pur­suit of 'in­hibit­ing the in­hibitor' in car­dio­vas­cu­lar dis­ease

4 years ago
Deals
R&D

‘Don’t want to fuss with this stuff’: An­oth­er DNA syn­the­sis start­up reels in fund­ing

4 years ago
Financing
Startups

Can a with­drawn Eli Lil­ly drug find sec­ond life in ra­dio­phar­ma? Lit­tle biotech hands over $5M cash to find out

4 years ago
Deals

How CMS in­de­pen­dence is at the fore­front of its Alzheimer's drug cov­er­age de­ci­sion

4 years ago
Pharma
FDA+

Car­lyle vaults in­to biotech in­vest­ing, buy­ing Abing­worth and launch­ing a new com­pa­ny aimed at piv­otal leaps

4 years ago
Deals

Ex­clu­sive: Flag­ship snags an­oth­er CEO-part­ner, on a per­son­al mis­sion, to lead its tR­NA boat

4 years ago
People
Startups

AACR22: As post-Covid de­vel­op­ment takes shape, BioN­Tech re­ports first hu­man da­ta for CAR-T/can­cer vac­cine com­bo

4 years ago
R&D
Cell/Gene Tx

AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

4 years ago
R&D
Pharma

AACR22: Af­fimed's NK cell ther­a­py pro­duces more pa­tient re­spons­es — and more dura­bil­i­ty ques­tions

4 years ago
R&D
Cell/Gene Tx

Biotechs take a beat­ing in first round of #AACR22 as weak da­ta crip­ple share prices

4 years ago
R&D

Ear­ly win­ner emerges at #AACR22 as a transat­lantic hy­brid posts an up­beat snap­shot for urothe­lial can­cer

4 years ago
R&D

Lat­est news on ‘dev­as­tat­ing’ Ab­b­Vie drug dis­con­tin­u­a­tion; Bio­gen's worst case sce­nario; Fi­nal­ly, some M&A; and ...

4 years ago
Weekly

Scoop: Ab­b­Vie drops IBS drug Viberzi in Cana­da, 'dev­as­tat­ing' pa­tients

4 years ago
Pharma
First page Previous page 551552553554555556557 Next page Last page
A service from the Financial Times